Dimerix Stock

Dimerix EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Dimerix (DXB.AX) as of Jul 19, 2026 is -9.58. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -17.56 — a change of -45.42% (higher).

EV/EBIT

-9.58

YoY

-45.42%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Dimerix is 2026 -9.58 . EV/EBIT (Enterprise Value to EBIT) of Dimerix was 2025 -17.56 . It decreases by -45.42% higher compared to the previous year.

The Dimerix EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-3.04 base
Jan 1, 2019
-7.02 base
Jan 1, 2020
-8.97 base
Jan 1, 2021
-7.67 base
Jan 1, 2022
-4.09 base
Jan 1, 2023
-4.85 base
Jan 1, 2024
-9.10 base
Jan 1, 2025
-9.94 base
YEARPRICE-TO-EBIT
2025 -9.94
2024 -9.10
2023 -4.85
2022 -4.09
2021 -7.67
2020 -8.97
2019 -7.02
2018 -3.04
2017 -5.95
2016 -7.31
2015 -4.73
2014 -4.73
2013 -6.58
2012 -9.56
2011 227.61
2010 -6.50
2009 -4.97
2008 -1.20
2007 -1.40
2006 -1.06
Access this data via the Eulerpool API

Dimerix Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Dimerix's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Dimerix's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Dimerix's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Dimerix grows earnings faster than its peers.

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

EV/EBIT (Enterprise Value to EBIT) of Dimerix is -9.58 in 2026.

Access this data via the Eulerpool API

Valuation — Dimerix

All Key Metrics — Dimerix